bristol myers squibb

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="5a9a58ca77cdac89feb80c6ebc580019"] .wpv-collage { grid-column-gap: 15px;grid-row-gap: 15px; } .wpv-view-output[data-toolset-views-view-editor="5a9a58ca77cdac89feb80c6ebc580019"] .wpv-collage > div:nth-child(4n + 1) { grid-area:  auto / auto / span 3 / span 7; } .wpv-view-output[data-toolset-views-view-editor="5a9a58ca77cdac89feb80c6ebc580019"] .wpv-collage > div:nth-child(4n + 2) { grid-area:  auto / auto / span 3 / span 5; } .wpv-view-output[data-toolset-views-view-editor="5a9a58ca77cdac89feb80c6ebc580019"] .wpv-collage > div:nth-child(4n + 3) { grid-area:  auto / auto / span 3 / span 5; } .wpv-view-output[data-toolset-views-view-editor="5a9a58ca77cdac89feb80c6ebc580019"] .wpv-collage > div:nth-child(4n + 4) { grid-area:  auto / auto / span 3 / span 7; } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="a552fc9653458e0d202e306ac0a1e0e3"] { text-align: left;justify-content: flex-start; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="40b05292f70a70284b1c1668151484af"] { background: rgba( 250, 246, 246, 1 );padding: 0px;border: 1px solid rgba( 218, 218, 218, 1 ); } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="15799f218876513e85a62246af23d50a"] { padding: 15px 20px 10px 20px;margin-top: 0px;border: 0px solid rgba( 0, 0, 0, 1 ); } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="d38c7b1e6196431e002ed2a380201dca"] .tb-button__link { background-color: rgba( 207, 46, 46, 1 );font-size: 12px;text-transform: capitalize; } .tb-button[data-toolset-blocks-button="d38c7b1e6196431e002ed2a380201dca"] .tb-button__icon { font-family: dashicons; } .tb-fields-and-text[data-toolset-blocks-fields-and-text="8d670a655444748b596f1fb0c7115269"] { color: rgba( 0, 0, 0, 1 );margin-bottom: 10px; } .tb-fields-and-text[data-toolset-blocks-fields-and-text="8d670a655444748b596f1fb0c7115269"] p { color: rgba( 0, 0, 0, 1 ); }  .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom} .wp-block-image.tb-image[data-toolset-blocks-image="7d618f72fcf8cf3093933d1e4b7feb11"] { max-width: 100%; } .wp-block-image.tb-image[data-toolset-blocks-image="7d618f72fcf8cf3093933d1e4b7feb11"] img { background-color: rgba( 250, 246, 246, 1 );border: 0px solid rgba( 0, 0, 0, 1 ); } @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="5a9a58ca77cdac89feb80c6ebc580019"] .wpv-collage > div:nth-child(3n + 1) { grid-area:  auto / auto / span 3 / span 12; } .wpv-view-output[data-toolset-views-view-editor="5a9a58ca77cdac89feb80c6ebc580019"] .wpv-collage > div:nth-child(3n + 2) { grid-area:  auto / auto / span 4 / span 6; } .wpv-view-output[data-toolset-views-view-editor="5a9a58ca77cdac89feb80c6ebc580019"] .wpv-collage > div:nth-child(3n + 3) { grid-area:  auto / auto / span 4 / span 6; } .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom} } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="5a9a58ca77cdac89feb80c6ebc580019"] .wpv-collage > div:nth-child(1n + 1) { grid-area:  auto / auto / span 6 / span 12; } .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom} } 

Elekta and BMS partner for digital treatment for melanoma

December 19, 2023
Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …

News

FDA approves BMS’s Augtyro for lung cancer treatment

November 16, 2023
Medical Communications FDA, Oncology, bristol myers squibb, lung cancer

Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for the treatment …

News

BMS acquires Mirati Therapeutics for $4.8bn

October 9, 2023
Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …

News

FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS

August 30, 2023
Research and Development FDA, Haematology, Reblozyl, anaemia, bristol myers squibb, myelodysplastic syndromes

Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the …

News

Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis

June 28, 2023
Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis

Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …

News

Bristol Myers Squibb’s NDA accepted by FDA

May 31, 2023
Medical Communications FDA, NDA, NSCLC, Oncology, bristol myers squibb

Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) has been accepted by the …

News

Bristol Myers Squibb building in New Jersey

Bristol Myers Squibb psoriasis drug shows positive Phase III results

April 29, 2021
Bristol-Myers Squibb, bristol myers squibb, pharma, pharma news, psoriasis, psoriasis treatment

Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown positive results in two Phase …

News

Molecular Templates signs cancer deal with BMS worth up to $1.3bn

February 15, 2021
Sales and Marketing Bristol-Myers Squibb, bristol myers squibb

Molecular Templates and Bristol Myers Squibb have entered into a worldwide strategic research collaboration worth up to $1.3 billion, to …

News

NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use

February 12, 2021
Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb

NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …

News

Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma

October 6, 2020
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Yervoy, bristol myers squibb, opdivo

Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line …

News

Bristol Myers Squibb announces positive results from Opdivo clinical trials

August 12, 2020
Research and Development Bristol-Myers Squibb, Cancer, bristol myers squibb

Bristol Myers Squibb has announced positive data from two Phase 3 clinical trials of its drug Opdivo. The first trial …

News

BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis

May 28, 2020
Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis

Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …

News

Phase 3 kidney cancer trial of Bristol Myers Squibb’s Opdivo and Exelixis’ Cabometyx meets primary endpoint

April 21, 2020
Manufacturing and Production BMS, Bristol-Myers Squibb, Exelixis, bristol myers squibb

Bristol Myers Squibb and Exelixis have announced that the Phase 3 trial investigating the combination of Opdivo (nivolumab) and Cabometyx …

News

Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute

April 14, 2020
Manufacturing and Production Bristol-Myers Squibb, Gilead, bristol myers squibb

A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company’s …

News

bristol myers squibb

Elekta and BMS partner for digital treatment for melanoma

FDA approves BMS’s Augtyro for lung cancer treatment

BMS acquires Mirati Therapeutics for $4.8bn

FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS

Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis

Bristol Myers Squibb’s NDA accepted by FDA

Bristol Myers Squibb psoriasis drug shows positive Phase III results

Molecular Templates signs cancer deal with BMS worth up to $1.3bn

NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use

Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma

Bristol Myers Squibb announces positive results from Opdivo clinical trials

BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis

Phase 3 kidney cancer trial of Bristol Myers Squibb’s Opdivo and Exelixis’ Cabometyx meets primary endpoint

Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute

Top Ten most popular articles on Pharmafile.com this week!

Latest content